Skip to main content

Table 1 Current European and Canadian guideline recommendations for lipids, lipoproteins, and baseline levels for study participants

From: Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

Parameter

Subjects without AVD

Subjects with AVD

 

Guidelines

Treatment group

Guidelines

Treatment group

 

CCS*

EU†high risk

E + A10

A20

CCS*

EU† very high risk

E + A10

A20

 

n = 66‡

n = 67‡

 

n = 449‡

n = 448‡

LDL-C

(mmol/L)

≤2.0 or

<2.5

3.25 (0.55)

3.11 (0.53)

≤2.0 or

<1.8

2.58 (0.70)

2.56 (0.49)

↓50%

↓50%

or ↓50%

Non-HDL-C

(mmol/L)

≤2.6

<3.3

4.04 (0.64)

3.84 (0.65)

≤2.6

<2.6

3.21 (0.76)

3.21 (0.61)

Apo B

(g/L)

≤0.8

<1.0

1.2 (0.2)

1.1 (0.2)

≤0.8

<0.8

1.0 (0.2)

1.0 (0.2)

  1. Baseline lipid and lipoprotein levels were determined for parameters common to CCS2012 and EU2012 targets.
  2. A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular disease; CCS, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe 10 mg; EU, European Guidelines (2012); LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.
  3. *Canadian guidelines specify that treatment targets should not change based on risk assessment.
  4. †European guidelines state that total cholesterol should be considered a treatment target if other analyses are not available.
  5. ‡n may vary slightly between measured parameters due to differences in available data.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X